

Product Number

926-09375

Storage: -20°C
prior to reconstitution;
4°C after reconstitution

Revised: March 2012

Updates available at:

<http://biosupport.licor.com>

**Limitation of Liability and
Limited Use Label License**

LI-COR IRDye® Infrared Dyes and reagent products are offered for research purposes only and are not intended for human therapeutic or diagnostic use. The purchase of this product conveys to the buyer the non-transferable right to use the amount of product purchased and the components of the product in research conducted by the buyer (whether the buyer is a not-for-profit, academic or for-profit entity). The buyer shall not sell or otherwise transfer this product, its components, or materials made there from to any third party. Buyer shall not use this product or its components for commercial purposes. The term "commercial purposes" shall mean any activity by a party for consideration and may include, but is not limited to, use of the product or its components (i) in manufacturing, (ii) to provide a service, information or data, (iii) for therapeutic, diagnostic or prophylactic purposes, or (iv) for resale, whether or not such product or its components are resold for use in research. The use of this product by the buyer constitutes agreement with the terms of this limited use label license for LI-COR IRDye infrared dyes and reagent products. Inquiries regarding the licensing of one or more IRDye infrared dyes should be submitted by e-mail to busdev@licor.com.

LI-COR BIOSCIENCES DOES NOT PROVIDE RESEARCH ADVICE OR DETERMINE OR RECOMMEND ANY POTENTIAL USES FOR IRDYE INFRARED DYES AND REAGENT PRODUCTS. LI-COR BIOSCIENCES MAKES NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AS TO ANY MATTER INCLUDING, BUT NOT LIMITED TO, WARRANTY OF FITNESS FOR PURPOSE, OR MERCHANTABILITY OR RESULTS OBTAINED FROM USE OF IRDYE INFRARED DYES. IN NO EVENT SHALL LI-COR BE LIABLE FOR LOST PROFITS, CONSEQUENTIAL, EXEMPLARY, SPECIAL, DIRECT, INCIDENTAL, OR PUNITIVE DAMAGES, OR ATTORNEY FEES, EVEN IF LI-COR HAD BEEN ADVISED OF, KNEW, OR SHOULD HAVE KNOWN, OF THE POSSIBILITIES THEREOF. NO EMPLOYEE, AGENT OR REPRESENTATIVE OF LI-COR HAS THE AUTHORITY TO BIND LI-COR TO ANY ORAL REPRESENTATION OR WARRANTY EXCEPT AS SPECIFICALLY SET FORTH HEREIN.

© 2012 LI-COR, Inc. LI-COR is an ISO 9001 registered company. LI-COR, BrightSite, IRDye, and BoneTag are trademarks and registered trademarks of LI-COR, Inc., in the United States and other countries. The Odyssey Infrared Imager, Pearl Imager, IRDye 800CW and IRDye reagents are covered by U.S. and foreign patents and patents pending.

Doc #988-12903

LI-COR®

Biosciences

4647 Superior Street • P.O. Box 4000
Lincoln, Nebraska 68504 USA
North America: 800-645-4267
International: 402-467-0700
FAX: 402-467-0819

LI-COR GmbH Germany, Serving Europe,
Middle East and Africa: +49 (0) 6172 17 17 771
LI-COR UK Ltd., Serving UK, Ireland, and
Scandinavia: +44 (0) 1223 422104
All other countries, contact LI-COR Biosciences
or a local LI-COR distributor:

<http://www.licor.com/distributors>

www.licor.com/bio

BrightSite™
Small Animal Imaging Agents

IRDye® 800CW BoneTag™ Optical Probe

Description

Calcium-chelating compounds have been used effectively for the detection of bone mineralization, growth, and morphological changes, including tetracycline derivatives, xylenol orange, alizarin, calcein, and fluorescein.¹⁻³

These characteristics have been used to produce a near infrared (NIR) optical bone marker for small animal imaging. By conjugating the BoneTag to IRDye 680RD and IRDye 800CW, we have extended the effective fluorescence signal detection to the NIR region without affecting the compound's ability to function as a marker of the mineralization process.

Using MC3T3-E1 (osteoblasts) in *in vitro* cell-based assays, the IRDye 800CW BoneTag shows specific binding characteristics. *In vivo* testing of IRDye 680RD and IRDye 800CW BoneTag optical probes are effective for skeletal labeling for imaging, which is unabated several weeks post-administration.

The ability to visualize bone anatomy/structures for an extended period facilitates the use of the bone targeting agent in conjunction with a second optical agent specific for a primary target (i.e., tumor tissue).

Material

The IRDye 800CW BoneTag solution was passed through a 0.2 µm nylon membrane into a sterile polypropylene tube and lyophilized. The product is supplied as a lyophilized powder from water in four tubes. The recommended individual dose per mouse (body weight ~25 g) will be approximately 2 nmol. Each of four tubes contains 10 nmol of IRDye 800CW BoneTag.

IRDye 800CW Properties (in 1X PBS)

- Absorption maximum: 780 nm
- Emission maximum: 795 nm
- Appearance: Lyophilized solid

Storage and Handling

Protect from light. Upon receipt, immediately store at -20°C prior to reconstitution. This product is stable in the lyophilized state for 3 months at -20°C. Reconstituted product should be used immediately.

Directions for Use

- Reconstitute material in 0.5 ml of sterile 1X PBS for a final concentration of 0.02 nmol/µL. If desired, filter sterilize the solution through a 0.2 µm filter system.
- Recommended administration: Inject 2 nmol (100 µL) intravenously via the tail vein or intraperitoneally.
- *In vivo* Imaging: It is important that unretained agent be allowed to clear from the animal's circulation prior to imaging. Suggested initial time frame for imaging is 24 hours post-injection. This agent will be visible for extended lengths of time (up to 6 weeks) post-injection. For best results, determine the optimal imaging time empirically.

Precautions

The probe is processed through the kidneys and excreted through the bladder.

References

- ¹Rahn, B. A. 2003. *European Cells and Materials* 5 (Suppl. 2):41.
- ²Malouvier, A., et al. 1993. *Med. Sci. Res.* 21:423-425.
- ³Lee, T. C., et al. 2003. *J. Anat.* 203:161-172.

This product is sold under license to LI-COR and covered by U. S. Patents 6,869,593 and 7,374,746.